¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"group specific C carbohydrate"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • group psychotherapy
    Áý´ÜÁ¤½Å¿ä¹ý
  • group reference value
    Áý´ÜÂü°íÄ¡
  • high risk group
    °íÀ§Ç豺
  • haptenic group
    ºÒ¿ÏÀüÇ׿ø±º, ÇÕÅÙ±º
  • linkage group
    ¿¬°ü±º
  • low risk group
    ÀúÀ§Ç豺
  • methyl group
    ¸ÞÆ¿±â
  • osmophore group
    ¹ßÇâ´Ü(Û¡úÅÓ¥)
  • prosthetic group
    1. º¸°áºÐÀÚ´Ü 2. º¸°á¿øÀÚ´Ü
  • Rh blood group system
    RhÇ÷¾×Çüü°è
  • soluble group
    °¡¿ëÇØ±º
  • self-help group
    ÀÚ°¡µµ¿òÁý´Ü
  • age-specific death rate
    ¿¬·Éº°»ç¸Á·ü
  • age-specific fertility rate
    ¿¬·Éº°»ý½Ä·ü
  • age-specific rate
    ¿¬·Éº°ºñÀ²
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • specific gravity
    ºñÁß
  • specific heat
    ƯÀÌ¿­
  • specific humidity
    ºñ½Àµµ
  • specific immunity
    ƯÀ̸鿪
  • specific inflammation
    ƯÀÌ¿°Áõ
  • specific inhibitor
    ƯÀ̾ïÁ¦Á¦
  • specific serotonin reuptake inhibitor
    ¼±ÅÃÀû¼¼·ÎÅä´ÑÀçÈí¼ö¾ïÁ¦Á¦
  • specific parasite
    ƯÀ̱â»ýÃæ
  • specific phobia
    ƯÁ¤°øÆ÷Áõ, ƯÁ¤°øÆ÷º´
  • specific photoelectricity
    ºñ±¤Àü´É
  • specific protein
    ƯÀ̴ܹéÁú
  • stage-specific protein
    ¹ßÀ°´Ü°èƯÀ̴ܹéÁú
  • species-specific reactivity
    Á¾Æ¯À̹ÝÀÀ¼º
  • specific radioactivity
    ƯÀ̹æ»ç´É
  • specific resistance
    ƯÀÌÀúÇ×
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Lutheran blood group system
    ·çÅͶõ Ç÷¾×Çü±º
  • P blood group system
    PÇ÷¾×Çü±º
  • Rh blood group
    RhÇ÷¾×Çü.
  • Rh blood group
    Rh Ç÷¾×Çü
  • Rh blood group system
    Rh Ç÷¾×Çü±º
  • amino group
    ¾Æ¹Ì³ë±â(¡­Ðñ).
  • analytic group psychotherapy
    ºÐ¼®Àû Áý´Ü Á¤½ÅÄ¡·á
  • anterior sinus group
    ÀüºÎºñµ¿±º
  • functional group
    ÀÛ¿ë±â(íÂéÄÐñ).
  • green or yellow vegetable group
    ³ìȲ»öä¼Ò·ù.
  • group
    ±º
  • group I fiber
    Á¦¥°¤Çí·A(ð¯ìéÏØàéë«).
  • group I fiber
    Á¦¥°±º¼¶À¯(ð¯ìéÏØàéë«).
  • group II fiber
    Á¦¥±¤Çí·A.
  • group II fiber
    Á¦¥± ±º¼¶À¯(ÏØàéë«).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • basic food group
    ±âÃʽÄǰ±º(¡­ãÝù¡ÏØ).
  • behavioral group therapy
    Áý´ÜÇൿġ·á(¿ä¹ý)
  • blood group
    Ç÷¾×Çü(úìäûúþ)
  • blood group =b. type
    Ç÷¾×Çü(Ì´ËâÌ´).
  • blood group =b. type
    Ç÷¾×Çü(úìäûû¡).
  • blood group incompatibility
    Ç÷¾×ÇüºÎÀûÇÕ.
  • blood group mucoids
    Ç÷¾×ÇüÁ¡Áú.
  • blood group polysaccharide
    Ç÷¾×Çü´Ù´ç·ù(¡­ÒýӨ׾).
  • blood group polysaccharide
    È­Ç÷¾×Çü´Ù´ç·ù(¡­ÒýӨ׾).
  • blood group system
    Ç÷¾×Çü±º
  • borderline group
    °æ°è±º(ÌÑÍ£ÏØ).
  • coliform group
    ´ëÀå±Õ±º
  • commutative group
    °¡È¯±º(˧̷˴).
  • commutator group
    ±³È¯ÀÚ±º(ÊÙË´).
  • complementation group
    »óº¸¼º Áý´Ü
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • specific retention volume
    ºñ Àú·ù ¿ëÀû(ÝïîÍ×µé»îÝ)
  • specific rotation
    ºñ¼±±¤µµ(ÝïàÁÎÃÓø)
  • specific rotatory power
    ºñ¼±±¤·Â(ÝïàÁÎÃÕô)
  • specific substrate concentration
    ƯÀÌ ±âÁú³óµµ(÷åì¶ÐñòõÒØÓø)
  • specific viscosity
    ºñÁ¡µµ(ÝïïÄÓø)
  • specific volumne
    ºñ¿ëÀû(Ýïé»îÝ)
  • tissue-specific enzyme
    Á¶Á÷ ƯÀÌ È¿¼Ò (ðÚòÄ÷åì¶ý£áÈ)
  • tumor-specific transplantation antigen
    Á¾¾çƯÀÌ ÀÌ½Ä Ç׿ø(ðþåË÷åì¶ì¹ãÕù÷ê«)
  • type-specific antigen
    ÇüƯÀÌ Ç׿ø(úþ÷åì¶ù÷ê«)
  • ABO blood group (type) system
    ABOÇ÷¾×Çü (úìäûúþ) ½Ã½ºÅÛ
  • acetyl group
    ¾Æ¼¼Æ¿±â(Ðñ)
  • acyl group
    ¾Æ½Ç±â(Ðñ)
  • alcoholic hydroxyl group
    ¾ËÄݼº(àõ) ÇÏÀ̵å·Ï½Ç±â(Ðñ)
  • aldehyde group
    ¾Ëµ¥ÇÏÀ̵å±â(Ðñ)
  • amino group
    ¾Æ¹Ì³ë±â(Ðñ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
GC ganglion cell; gas chromatography; general circulation; general closure; general condition; generali...
Gc gigacycle; gonococcus; group-specific component
gs group specific
GSA general somatic afferent; group-specific antigen; Gross virus antigen; guanidinosuccinic acid
AGPA American Group Practice Association; American Group Psychotherapy Association
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
Group A group 1
group B group A
Group D group
Group I group
group II group I
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • donor-specific phage
    °ø¿©±Õ ƯÀÌ ÆÄÁö
  • nociceptive specific
    Ä§ÇØ ¼ö¿ë¼º ƯÀ̼º, À¯ÇØ ¼ö¿ë¼º ƯÀ̼º
  • nociceptive-specific cell
    Ä§ÇØ ¼ö¿ë-ƯÀ̼º ¼¼Æ÷, À¯ÇØ ¼ö¿ë-ƯÀ̼º ¼¼Æ÷
  • nociceptive-specific neuron
    Ä§ÇØ ¼ö¿ë-ƯÀ̼º ´º¿ì·±, À¯ÇØ ¼ö¿ë-ƯÀ̼º ´º¿ì·±
  • non-specific arousal system
    ºñƯÀ̼º °¢¼º°è
  • non-specific response
    ºñƯÀ̼º ¹ÝÀÀ
  • specific
    ƯÀÌÇÑ, Á¾ÀÇ, Á¾Á·ÀÇ, ƯÀÌÀÇ, ƯÀ̼ºÀÇ, ƯÀÌÀûÀÎ
    1. ÇÑ Á¾·ùÀÇ ¹Ì»ý¹°¿¡ ÀÇÇØ¼­ »ê»ýµÇ´Â. 2. Ư¼ö¼ºÀÇ. Àû¿ë, È¿°ú µîÀÌ Æ¯Á¤ÇÑ ±¸Á¶, ±â´É µî¿¡ ÇÑÁ¤µÈ. 3. ƯȿÀÇ ¾î¶² ƯÁ¤ Áúȯ¿¡ ´ëÇØ¼­ Ưº°È÷ À¯È¿ÇÑ ÀǾàǰ. 4. ¸é¿ªÇп¡ À־ ´ëÀÀÇÏ´Â Ç×ü¿¡ ´ëÇÑ Ç׿øÀÇ Æ¯º°ÇÑ Ä£È­¼º¿¡ °üÇÑ.
  • specific activity
    ƯÀÌ È°¼º, ƯÀÌ È°¼ºµµ, ºñȰ¼º, ºñȰ¼ºµµ
  • specific alopecia
    Ư¼ö Å»¸ðÁõ
  • specific congenital heart defects
    °³º° º´¼Ò
  • specific criteria
    ƯÀÌÇÑ ±âÁØ
  • specific dentist-patient relationship
    µ¶Æ¯ÇÑ Ä¡°ú ÀÇ»ç-ȯÀÚ °ü°è
  • specific energy of sense
    Ư¼ö °¨°¢ ¿¡³ÊÁö
  • specific gamma emission
    Ư¼ö °¨¸¶ ¹æÃâ
  • specific gravity test
    ºñÁß ½ÃÇè
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
pregnancy-specific beta 1-glycoprotein A glycoprotein with the electrophoretic mobility of a beta-1 globulin. It is produced by the placental trophoblast and secreted into the maternal bloodstream during pregnancy. It can be detected 18 days after ovulation and its concentration in plasma rises steadily until, at the end of gestation, it reaches 200 mg/ml. It has been proposed as a measure of placental function for fertility control and is a candidate for an early pregnancy test.
(12 Dec 1998)
prenylated peptide-specific endoprotease <enzyme> Cleaves c-terminal tripeptide from prenylated protein having c-terminal sequence caax; race is rac and a-factor converting enzyme with same activity
Registry number: EC 3.4.14.-
Synonym: prenylated protein endoprotease, race enzyme, isoprenylated protein endopeptidase, isoprenylated protein endoprotease
(26 Jun 1999)
cytosol non-specific dipeptidase <enzyme> Also referred to as peptidase a (see synonym to penicillopepsin, EC 3.4.23.20)
Registry number: EC 3.4.13.-
Synonym: glycyl-l-leucine hydrolase, glycylleucine dipeptidase, gly-leu dipeptide peptidase, dipeptide hydrolase, glycyl-leucine dipeptidase
(26 Jun 1999)
cytotoxic T lymphocyte-specific serine protease <enzyme> Structural sequence given in first source
Registry number: EC 3.4.21.-
Synonym: cytotoxic t lymphocyte-specific serine protease ccp I, cytotoxic t lymphocyte specific serine protease ccp II, mast cell protease type II
(26 Jun 1999)
proline-specific dipeptidylcarboxypeptidase <enzyme> From streptomyces species; removes diproline form c-terminus of proline-containing peptides such as boc-pro-pro-pro-pro or leu-pro-pro-pro-pro-pro
Registry number: EC 3.4.15.-
Synonym: pro-dpp-carboxypeptidase
(26 Jun 1999)
prostate-specific antigen <tumour marker> A simple blood test used to detect prostate cancer in men. The test measures a specific antigen normally secreted by the prostate. If cancer is developing, the prostate secretes greater amounts of prostate-specific antigen. This test is recommended for men with an enlarged prostate and an increased risk of prostate cancer.
It is an enzyme that is produced by epithelial cells of both benign and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
It is a single chain 31 kilodalton glycoprotein with 240 amino acid residues and 4 carbohydrate side chains that is a kallikrein protease.
It is found in normal seminal fluid and produced by the prostatic epithelial cells.
Elevated levels in blood serum are associated with prostatic enlargement and prostatic adenocarcinoma, and this allows early detection of cancer in many cases. In about 70% of cases, the rise is due to a cancerous condition.
No large scale clinical studies have been completed to assess the impact of testing on survival from prostate cancer, and the medical and economic value of testing remain uncertain.
Acronym: PSA
Registry number: EC 3.4.21.77
(22 Sep 2002)
pyrimidine-guanine sequence-specific ribonuclease <enzyme> From yolk granules of adult rana catesbeiana oocytes
Registry number: EC 3.1.27.-
Synonym: rc-rnase, rana catesbeiana rnase
(26 Jun 1999)
site-specific mutagenesis <cell culture, molecular biology> An in vitro technique in which an alteration is made at a specific site in a DNA molecule, which is then reintroduced into a cell. Various techniques are used, for the cell biologist, a very powerful approach to determining which parts of a protein or nucleotide sequence are critical to function.
(18 Nov 1997)
site specific mutation An alteration of the structure of a gene at a specific sequence, usually referring to experimentally produced changes in gene sequence.
(05 Mar 2000)
site-specific recombination <molecular biology> A type of recombination that occurs between two specific short DNA sequences present in the same or in different molecules. An example is the integration and excision of _ prophage.
(18 Nov 1997)
soluble specific substance A soluble type-specific polysaccharide produced during active growth of virulent pneumococci composing a large part of the capsule.
Synonym: pneumococcal polysaccharide, soluble specific substance, specific soluble polysaccharide, specific soluble sugar.
(05 Mar 2000)
species-specific Applying only to a particular species, said of effects that vary depending on the species in question.
(09 Oct 1997)
species-specific antigen Antigenic components in the tissues and fluids of members of a species of animal, by means of which various species may be immunologically distinguished; e.g., serum albumin of horses is immunologically different from that of man, dogs, sheep, and so on.
(05 Mar 2000)
specific 1. Pertaining to a species.
2. Produces by a single kind of microorganism.
3. A remedy specially indicated for any particular disease.
4. <immunology> Pertaining to the special affinity of antigen for the corresponding antibody.
Origin: L. Specificus
(18 Nov 1997)
specific absorbance Absorbance per unit of concentration.
See: specific absorption coefficient.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • group practice
    (¿©·¯ Àü¹®ÀÇÀÇ)Áý´Ü ÀÇ·á;(¿©·¯ ȯÀÚ¿¡ ´ëÇÑ)Áý´Ü °ËÁø ,
  • group psychology
    ±ºÁß ½É¸®ÇÐ
  • group sex
    Áý´Ü ¼º±³
  • group theory
    ±º·Ð
  • group therapy
    Áý´Ü ¿ä¹ý
  • group velocity
    (ÆÄµ¿ÀÇ)±º¼Óµµ
  • group work
    Áý´Ü(»çȸ)»ç¾÷
  • habitat group
    »ýÅ·ù(¼­½Ä ȯ°æÀ» °°ÀÌ ÇÏ´Â µ¿½Ä¹°);(¹Ú¹°°ü¿¡ Àü½ÃµÈ)»ý¹° ȯ°æ ¸ðÇü
  • income group
    »çȸ ¼ÒµæÃþ(µ¿ÀÏ ¼Òµæ¼¼¾×Áý´Ü)
  • informal group
    (»çȸ)ºñ°ø½ÄÀû Áý´Ü(°üû°øÀåµî¿¡¼­ÀÇ)
  • interested group
    (»çȸ)ÀÌÀͰøµ¿Ã¼;°øÅëÀÌÇØ´Üü(±¹°¡ Á¤´çŬ·´µî)
  • minority group
    ¼Ò¼ö¹ÎÁ·(Çѳª¶óÀÇ)
  • peer group
    µ¿·á Áý´Ü;µ¿¹è Áý´Ü
  • pressure group
    ¾Ð·Â ´Üü
  • primary group
    Á¦ ÀÏÂ÷ Áý´Ü(°¡Á¤,Ä£±¸ µî)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á